NeuroAdjuvants Overview

  • Founded
  • 2005
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

NeuroAdjuvants General Information


Developer of peptide-based therapeutics intended to offer therapeutics for neurological treatment. The company's peptide-based therapeutics is produced by research and development of neuropeptide-based therapeutics for the treatment of neurological, psychiatric, metabolic and inflammatory disorders, enabling healthcare sectors to provide proper treatment for neurological diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Primary Office
  • 417 Wakara Way
  • Suite 3510
  • Salt Lake City, UT 84108
  • United States
+1 (801) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroAdjuvants Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 29-Nov-2018 00.00 Completed Out of Business
3. Grant 26-Mar-2009 00.00 Completed Startup
2. Early Stage VC (Series A2) 27-Jun-2007 $1000K $1.2M 00.00 Completed Startup
1. Early Stage VC (Series A1) 22-Jan-2007 $200K $200K 00.00 Completed Startup
To view NeuroAdjuvants’s complete valuation and funding history, request access »

NeuroAdjuvants Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2 000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A1 000,000 00.000000 00 00 00 00 0.000
To view NeuroAdjuvants’s complete cap table history, request access »